N-(2-diethylaminoethyl)-2-[2-(2-(2,3-difluorophenyl)ethyl)-4-oxo-4,5,6,7-tetrahydro-cyclopentapyrimidin-1-yl]-N-(4'-trifluoromethyl-biphenyl-4-ylmethyl)acetamide | 412960-98-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(2-diethylaminoethyl)-2-[2-(2-(2,3-difluorophenyl)ethyl)-4-oxo-4,5,6,7-tetrahydro-cyclopentapyrimidin-1-yl]-N-(4'-trifluoromethyl-biphenyl-4-ylmethyl)acetamide
• 英文别名: N-[2-(diethylamino)ethyl]-2-[2-[2-(2,3-difluorophenyl)ethyl]-4-oxo-6,7-dihydro-5H-cyclopenta[d]pyrimidin-1-yl]-N-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide
• CAS: 412960-98-6
• 化学式: C₃₇H₃₉F₅N₄O₂
• 分子量: 666.734
• InChiKey: FKEVAONXMSBRMZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.5
• 重原子数：
  48
• 可旋转键数：
  13
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  56.2
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  D-酒石酸 、 N-(2-diethylaminoethyl)-2-[2-(2-(2,3-difluorophenyl)ethyl)-4-oxo-4,5,6,7-tetrahydro-cyclopentapyrimidin-1-yl]-N-(4'-trifluoromethyl-biphenyl-4-ylmethyl)acetamide 以 甲醇 为溶剂， 以0.49 g的产率得到N-[2-(diethylamino)ethyl]-2-{2-[2-(2,3-difluorophenyl)ethyl]-4-oxo-4,5,6,7-tetrahydro-1H-cyclopenta[d]pyrimidin-1-yl}-N-{[4'-(trifluoromethyl)-4-biphenylyl]methyl}acetamide bitartrate
  参考文献：
  名称：

  USE OF LP-PLA2 INHIBITORS IN THE TREATMENT AND PREVENTION OF EYE DISEASES

  摘要：

  公开号：

  EP2651403B1
• 作为产物：
  描述：

  2-(2-[2-(2,3-difluorophenyl)ethyl]-4-oxo-4,5,6,7-tetrahydro-cyclopentapyrimidin-1-yl)acetic acid 、 N,N-二-N′-(4′-三氟甲基联苯-4-甲基)-乙烷-1,2-二胺 在 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 以52%的产率得到N-(2-diethylaminoethyl)-2-[2-(2-(2,3-difluorophenyl)ethyl)-4-oxo-4,5,6,7-tetrahydro-cyclopentapyrimidin-1-yl]-N-(4'-trifluoromethyl-biphenyl-4-ylmethyl)acetamide
  参考文献：
  名称：

  METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS

  摘要：

  本发明提供了一种用于治疗和预防神经退行性疾病和神经相关疾病的组合物和方法，通过抑制Lp-PLA2。这些组合物和方法可用于治疗和预防具有异常血脑屏障（BBB）功能的疾病和疾病，例如具有可渗透BBB的神经退行性疾病，如但不限于阿尔茨海默病、亨廷顿病、帕金森病和血管性痴呆症。

  公开号：

  EP2977452A3

文献信息

• METHODS OF TREATMENT AND PREVENTION OF METABOLIC BONE DISEASES AND DISORDERS
  申请人：SHI Yi

  公开号：US20080280829A1

  公开（公告）日：2008-11-13

  The present invention provides compostions and methods useful for treating and preventing metabolic bone diseases and disorders by inhibition of Lp-PLA 2 . The compositions and methods are useful for treating and preventing metabolic bone diseases and disorders such as, for example osteoporosis, osteopenia and osteopenia related diseases and abnormal bone marrow.

  本发明提供了用于治疗和预防代谢性骨疾病和紊乱的组合物和方法，通过抑制Lp-PLA2。这些组合物和方法可用于治疗和预防代谢性骨疾病和紊乱，例如骨质疏松症、骨质疏松症和相关疾病以及异常骨髓。
• METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS
  申请人：SHI Yi

  公开号：US20080279846A1

  公开（公告）日：2008-11-13

  The present invention provides compostions and methods useful for treating and preventing neurodegenerative disease and neurologically related disorders by inhibition of Lp-PLA2. The compositions and methods are useful for treating and preventing diseases and disorders with abnormal blood brain barrier (BBB) function, for example neurodegenerative diseases with a permeable BBB, such as but not limited to, Alzheimer's Disease, Huntington's Disease, Parkinson's Disease and Vascular Dementia.

  本发明提供了一种用于治疗和预防神经退行性疾病和神经相关疾病的组合物和方法，通过抑制Lp-PLA2。这些组合物和方法可用于治疗和预防具有异常血脑屏障（BBB）功能的疾病和疾病，例如具有可渗透性BBB的神经退行性疾病，例如但不限于阿尔茨海默病、亨廷顿病、帕金森病和血管性痴呆症。
• Pyrimidinone Derivatives and Their Use in the Treatment of Atherosclerosis
  申请人：Elliott Leonard Richard

  公开号：US20060241126A1

  公开（公告）日：2006-10-26

  Compounds of formula (I): are inhibitors of the enzyme Lp-PLA 2 and are of use in therapy, in particular for treating atherosclerosis.

  公式为（I）的化合物是Lp-PLA2酶的抑制剂，可用于治疗，特别是用于治疗动脉粥样硬化。
• METHODS OF TREATMENT OF SKIN ULCERS
  申请人：Wilensky Robert

  公开号：US20100239565A1

  公开（公告）日：2010-09-23

  Methods for treating and/or preventing skin ulcers are provided featuring administration of pharmaceutical compositions comprising inhibitors of activity or expression Of Lp-PLA 2 protein to patients subject to or at risk of developing skin ulcers.

  提供了治疗和/或预防皮肤溃疡的方法，其中包括给予含有Lp-PLA2蛋白质活性或表达抑制剂的药物组合物给予患有或有发展皮肤溃疡风险的患者。
• PYRIMIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ATHEROSCLEROSIS
  申请人：SMITHKLINE BEECHAM PLC

  公开号：EP1337517B1

  公开（公告）日：2008-11-26